Synthesis of coelenterazine analogs for dynamic in vivo imaging of calcium signaling -Synthesis of (-)-EGCG analogs as Dyrk1a inhibitors in the symptomatic therapy of Down syndrome

Au cours de cette thèse, deux sujets distincts ont été étudiés : d’une part la synthèse d’analogues de la coelentérazine, substrat de différentes luciférases, pour une application en imagerie in vivo, et d’autre part la synthèse d’analogues du (-)-EGCG, inhibiteur de la kinase Dyrk1a, impliquée notamment dans les troubles cognitifs rencontrés dans la trisomie 21.La problématique du premier sujet consistait à obtenir des analogues de la coelentérazine conservant leur activité sur deux luciférases, la luciférase Renilla et l’aequorine, tout en induisant un déplacement vers le rouge de la bioluminescence produite par ces enzymes. L’aequorine, sensible au calcium, représentait la cible biologique principale du projet.Sept analogues dont six originaux ont été obtenues par des méthodes de synthèse classiques, et leurs activités ont pu être testées sur les deux luciférases choisies, avec des résultats probants : malgré des émissions de lumière moins intenses que celles obtenues avec la coelentérazine native, plusieurs molécules ont entrainé un déplacement vers le rouge de la longueur d’onde d’émission de lumière par bioluminescence allant jusqu’à 27 nm pour l’aequorine et plus de 120 nm pour la luciférase Renilla.Le second sujet, de chimie médicinale classique, a principalement consisté à la synthèse d’analogues du gallate d’épigallocatéchine (EGCG) au squelette simplifié, et au sein desquels le cycle pyranique caractéristique des catéchines a été remplacé par un carbocycle. Plusieurs molécules ont pu être synthétisées, dont deux présentant le motif hexaphénol. Leur activité inhibitrice de Dyrk1a a pu être testée in vitro et l’une d’entre elle s’est déjà révélée plus active que l’EGCG.During this thesis, two distinct projects were studied: on the one hand, the synthesis of coelenterazine analogs, substrate of several luciferases, in the purpose of using them for in vivo imaging, and on the other, the synthesis of (-)-EGCG analogs, inhibitor of the Dyrk1a kinase, which interests us for the role it plays in the mental retardation existing in the Down Syndrome disease.The problematic of the first project consisted in obtaining coelenterazine analogs that would not only maintain their activity on two luciferases, the Renilla luciferase and aequorine, but they should also induce a red-shift of the bioluminescence produced by these enzymes. Because of its sensitivity to calcium, aequorine was the main biologic target of this project.Seven analogs, of which six had an original structure, were synthesized through usual synthetic methodologies and their activities on both aequorine and Renilla luciferase were tested in vitro, with interesting results: even if the intensities of light emission were weaker than those obtained with native coelenterazine, several molecules produced a red-shift of the emission wavelength of bioluminescence, up to 27nm for aequorine and more than 120nm for the Renilla luciferase. The second project, of classical medicinal chemistry, mainly consisted in the synthesis of epigallocatechin gallate analogs (EGCG) with a simplified backbone and in which the pyranic ring typical of catechins was replaced by a carbocycle. Several molecules were synthesized, two of them possessing the hexaphenol motif. Their inhibiting activity of Dyrk1a was tested in vitro and one already showed a better activity than natural EGCG

Synthèse d'analogues de la coelentérazine pour l'imagerie in vivo dynamique des signaux calciques - Synthèse d'analogues du (-)-EGCG comme inhibiteurs de Dyrk1a dans la thérapie symptomatique de la trisomie 21

Au cours de cette thèse, deux sujets distincts ont été étudiés : d une part la synthèse d analogues de la coelentérazine, substrat de différentes luciférases, pour une application en imagerie in vivo, et d autre part la synthèse d analogues du (-)-EGCG, inhibiteur de la kinase Dyrk1a, impliquée notamment dans les troubles cognitifs rencontrés dans la trisomie 21.La problématique du premier sujet consistait à obtenir des analogues de la coelentérazine conservant leur activité sur deux luciférases, la luciférase Renilla et l aequorine, tout en induisant un déplacement vers le rouge de la bioluminescence produite par ces enzymes. L aequorine, sensible au calcium, représentait la cible biologique principale du projet.Sept analogues dont six originaux ont été obtenues par des méthodes de synthèse classiques, et leurs activités ont pu être testées sur les deux luciférases choisies, avec des résultats probants : malgré des émissions de lumière moins intenses que celles obtenues avec la coelentérazine native, plusieurs molécules ont entrainé un déplacement vers le rouge de la longueur d onde d émission de lumière par bioluminescence allant jusqu à 27 nm pour l aequorine et plus de 120 nm pour la luciférase Renilla.Le second sujet, de chimie médicinale classique, a principalement consisté à la synthèse d analogues du gallate d épigallocatéchine (EGCG) au squelette simplifié, et au sein desquels le cycle pyranique caractéristique des catéchines a été remplacé par un carbocycle. Plusieurs molécules ont pu être synthétisées, dont deux présentant le motif hexaphénol. Leur activité inhibitrice de Dyrk1a a pu être testée in vitro et l une d entre elle s est déjà révélée plus active que l EGCG.During this thesis, two distinct projects were studied: on the one hand, the synthesis of coelenterazine analogs, substrate of several luciferases, in the purpose of using them for in vivo imaging, and on the other, the synthesis of (-)-EGCG analogs, inhibitor of the Dyrk1a kinase, which interests us for the role it plays in the mental retardation existing in the Down Syndrome disease.The problematic of the first project consisted in obtaining coelenterazine analogs that would not only maintain their activity on two luciferases, the Renilla luciferase and aequorine, but they should also induce a red-shift of the bioluminescence produced by these enzymes. Because of its sensitivity to calcium, aequorine was the main biologic target of this project.Seven analogs, of which six had an original structure, were synthesized through usual synthetic methodologies and their activities on both aequorine and Renilla luciferase were tested in vitro, with interesting results: even if the intensities of light emission were weaker than those obtained with native coelenterazine, several molecules produced a red-shift of the emission wavelength of bioluminescence, up to 27nm for aequorine and more than 120nm for the Renilla luciferase. The second project, of classical medicinal chemistry, mainly consisted in the synthesis of epigallocatechin gallate analogs (EGCG) with a simplified backbone and in which the pyranic ring typical of catechins was replaced by a carbocycle. Several molecules were synthesized, two of them possessing the hexaphenol motif. Their inhibiting activity of Dyrk1a was tested in vitro and one already showed a better activity than natural EGCG.PARIS11-SCD-Bib. électronique (914719901) / SudocSudocFranceF

[(NHC)Au-I]-Catalyzed rearrangement of allylic acetates

{NHC)AuCl] complexes (NHC = N-heterocyclic carbene), in conjunction with a silver salt, were found to efficiently catalyze the rearrangement of allylic acetates under both conventional and microwave-assisted heating. The optimization of several reaction parameters (solvent, silver salt, and ligand) as well as a study of the reaction scope are reported. The steric hindrance of the ligand bound to gold was found crucial for the outcome of the reaction as only extremely bulky ligands permitted the isomerization

[(NHC)Au-I]-catalyzed formation of conjugated enones and enals : an experimental and computational study

The [(NHC)Au-I]-catalyzed (NHC = N-heterocyclic carbene) formation of a,p-unsaturated carbonyl compounds (enones and enals) from propargylic acetates is described. The reactions occur at 60 degrees C in 8 h in the presence of an equimolar mixture of [(NHC)AuCl] and AgSbF6 and produce conjugated enones and enals in high yields. Optimization studies revealed that the reaction is sensitive to the solvent, the NHC, and, to a lesser extent, to the silver salt employed, leading to the use of [(ItBu)AuCl]/AgSbF6 in THF as an efficient catalytic system. This transformation proved to have a broad scope, enabling the stereoselective formation of (E)-enones and -enals with great structural diversity. The effect of substitution at the propargylic and acetylenic positions has been investigated, as well as the effect of aryl substitution on the formation of cinnamyl ketones. The presence or absence of water in the reaction mixture was found to be crucial. From the same phenylpropargyl acetates, anhydrous conditions led to the formation of indene compounds via a tandem [3,3] sigmatropic rearrangement/intramolecular hydroarylation process, whereas simply adding water to the reaction mixture produced enone derivatives cleanly. Several mechanistic hypotheses, including the hydrolysis of an allenol ester intermediate and S(N)2' addition of water, were examined to gain an insight into this transformation. Mechanistic investigations and computational studies support [(NHC)AuOH], produced in situ from [(NHC)AuSbF6] and H2O, instead of cationic [(NHC)AuSbF6] as the catalytically active species. Based on DFT calculations performed at the B3LYP level of theory, a full catalytic cycle featuring an unprecedented transfer of the OH moiety bound to the gold center to the C C bond leading to the formation of a gold-allenolate is proposed

Kinetic Target-Guided Synthesis: Reaching the Age of Maturity

International audienceKinetic target-guided synthesis (KTGS) is an original discovery strategy allowing a target to catalyze the irreversible synthesis of its own ligands from a pool of reagents. Though pioneered almost two decades ago, it only recently proved its usefulness in medicinal chemistry, as exemplified by the increasing number of protein targets used, the wider range of target and pocket types, and the diversity of therapeutic areas explored. In recent years, two new leads for in vivo studies were released. Amidations and multicomponent reactions expanded the armamentarium of reactions beyond triazole formation and two new examples of in cellulo KTGS were also disclosed. Herein, we analyze the origins and the chemical space of both KTGS ligands and warhead-bearing reagents. We review the KTGS timeline focusing on recent cases in order to give medicinal chemists the full scope of this strategy which has great potential for hit discovery and hit or lead optimization

Crystal structures of ERAP2 complexed with inhibitors reveal pharmacophore requirements for optimizing inhibitor potency

Endoplasmic reticulum aminopeptidase 2 assists with the generation of antigenic peptides for presentation onto Major Histocompatibility Class I molecules in humans. Recent evidence has suggested that the activity of ERAP2 may contribute to the generation of autoimmunity, thus making ERAP2 a possible pharmacological target for the regulation of adaptive immune responses. To better understand the structural elements of inhibitors that govern their binding affinity to the ERAP2 active site, we cocrystallized ERAP2 with a medium activity 3,4-diaminobenzoic acid inhibitor and a poorly active hydroxamic acid derivative. Comparison of these two crystal structures with a previously solved structure of ERAP2 in complex with a potent phosphinic pseudopeptide inhibitor suggests that engaging the substrate N-terminus recognition properties of the active site is crucial for inhibitor binding even in the absence of a potent zinc-binding group. Proper utilization of all five major pharmacophores is necessary, however, to optimize inhibitor potency.</p